FBR & Co Analysts Increase Earnings Estimates for Infinity Pharmaceuticals Inc. (INFI)
Infinity Pharmaceuticals Inc. (NASDAQ:INFI) – Stock analysts at FBR & Co raised their Q3 2016 earnings per share (EPS) estimates for shares of Infinity Pharmaceuticals in a note issued to investors on Monday. FBR & Co analyst C. James now forecasts that the firm will post earnings per share of ($0.88) for the quarter, up from their prior forecast of ($0.89). FBR & Co has a “Hold” rating on the stock. FBR & Co also issued estimates for Infinity Pharmaceuticals’ FY2016 earnings at ($3.60) EPS.
Several other brokerages have also issued reports on INFI. Zacks Investment Research upgraded shares of Infinity Pharmaceuticals from a “hold” rating to a “buy” rating and set a $1.75 price target for the company in a research note on Tuesday, August 16th. Wedbush reiterated a “neutral” rating and issued a $1.00 price target (down from $1.25) on shares of Infinity Pharmaceuticals in a research note on Tuesday, August 9th. Finally, Morgan Stanley reiterated a “hold” rating and issued a $1.00 price target on shares of Infinity Pharmaceuticals in a research note on Thursday, August 11th. Nine equities research analysts have rated the stock with a hold rating and one has issued a buy rating to the company’s stock. Infinity Pharmaceuticals has a consensus rating of “Hold” and an average target price of $4.56.
Infinity Pharmaceuticals (NASDAQ:INFI) traded up 1.46% on Wednesday, reaching $1.39. 72,571 shares of the company’s stock were exchanged. The firm’s 50 day moving average price is $1.49 and its 200 day moving average price is $2.95. The company has a market cap of $68.93 million, a PE ratio of 4.47 and a beta of 1.89. Infinity Pharmaceuticals has a 52-week low of $1.24 and a 52-week high of $10.85.
This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at https://www.americanbankingnews.com/2016/10/19/fbr-co-analysts-increase-earnings-estimates-for-infinity-pharmaceuticals-inc-infi.html
Infinity Pharmaceuticals (NASDAQ:INFI) last released its earnings results on Tuesday, August 9th. The company reported $1.05 earnings per share for the quarter, beating the Zacks’ consensus estimate of ($0.89) by $1.94. The firm had revenue of $9.47 million for the quarter, compared to analysts’ expectations of $13.91 million. Infinity Pharmaceuticals had a net margin of 13.23% and a negative return on equity of 55.51%. The company’s quarterly revenue was up 94.1% on a year-over-year basis. During the same period in the previous year, the company earned ($0.78) earnings per share.
Several hedge funds have recently made changes to their positions in the stock. Evercore Wealth Management LLC increased its stake in shares of Infinity Pharmaceuticals by 14.0% in the second quarter. Evercore Wealth Management LLC now owns 107,091 shares of the company’s stock worth $142,000 after buying an additional 13,157 shares during the last quarter. Numeric Investors LLC increased its stake in shares of Infinity Pharmaceuticals by 699.4% in the second quarter. Numeric Investors LLC now owns 843,823 shares of the company’s stock worth $1,122,000 after buying an additional 738,269 shares during the last quarter. BVF Inc. IL bought a new stake in shares of Infinity Pharmaceuticals during the second quarter worth about $6,896,000. A.R.T. Advisors LLC bought a new stake in shares of Infinity Pharmaceuticals during the second quarter worth about $210,000. Finally, State Street Corp increased its stake in shares of Infinity Pharmaceuticals by 18.3% in the second quarter. State Street Corp now owns 1,026,314 shares of the company’s stock worth $1,367,000 after buying an additional 158,687 shares during the last quarter. 80.86% of the stock is currently owned by hedge funds and other institutional investors.
Infinity Pharmaceuticals Company Profile
Infinity Pharmaceuticals, Inc is a biopharmaceutical company. The Company is engaged in the discovery, development and delivery of medicines to treat diseases. The Company develops small molecule drugs that target disease pathways for potential applications in oncology. Its product candidate is duvelisib, also known as IPI-145, is an oral, dual-inhibitor of the delta and gamma isoforms of phosphoinositide-3-kinase (PI3K), for the treatment of hematologic malignancies, or blood cancers.
Receive News & Ratings for Infinity Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Infinity Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.